再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

交易中 04-04 10:47:37 EDT

596.85

-13.79

-2.26%

最高610.65	最低595.63	成交量31.87万
今开610.65	昨收610.64	日振幅2.46%
总市值652.50亿	流通市值626.69亿	总股本1.09亿
成交额1.92亿	换手率0.30%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":596.85,"timestamp":1743778056992,"preClose":610.64,"halted":0,"volume":318740,"delay":0,"floatShares":105000000,"shares":109324682,"eps":38.34,"marketStatus":"交易中","change":-13.79,"latestTime":"04-04 10:47:37 EDT","open":610.65,"high":610.65,"low":595.6301,"amount":192165827.954,"amplitude":0.024597,"askPrice":597.74,"askSize":1,"bidPrice":595.71,"bidSize":101,"shortable":3,"etf":0,"ttmEps":38.34,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1743796800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":610.64,"preHourTrading":{"tag":"盘前","latestPrice":614.85,"preClose":610.64,"latestTime":"09:29 EDT","volume":12474,"amount":7609829.8122,"timestamp":1743773351939},"postHourTrading":{"tag":"盘后","latestPrice":610.64,"preClose":610.64,"latestTime":"19:58 EDT","volume":14209,"amount":8675872.2501,"timestamp":1743724690928},"volumeRatio":1.632089,"impliedVol":0.538,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2524278865","title":"再生元制药公司跌1.84% 股价跌破600美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2524278865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2524278865?lang=zh_cn&edition=full","pubTime":"2025-04-04 21:50","pubTimestamp":1743774604,"startTime":"0","endTime":"0","summary":"北京时间2025年04月04日21时50分，再生元制药公司股票出现异动，股价快速跳水1.84%。截至发稿，该股报599.42美元/股，成交量13.7346万股，换手率0.13%，振幅1.84%。最近的财报数据显示，该股实现营业收入142.02亿美元，净利润44.13亿美元，每股收益40.90美元，毛利117.51亿美元，市盈率15.63倍。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.93%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250404215004972e7ddf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2089984988.USD","LU2468319806.SGD","LU0058720904.USD","LU2237438978.USD","LU0320765992.SGD","LU2362541273.HKD","LU0823416689.USD","LU2106854487.HKD","BK4585","LU0289739699.SGD","LU2023250504.SGD","LU0882574055.USD","BK4588","LU2362540622.SGD","LU1917777945.USD","LU1974910355.USD","REGN","BK4139","LU0114720955.EUR","LU2362541513.USD","LU0053666078.USD","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2524766864","title":"再生元制药公司4月2日成交额为5.61亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524766864","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2524766864?lang=zh_cn&edition=full","pubTime":"2025-04-03 10:24","pubTimestamp":1743647067,"startTime":"0","endTime":"0","summary":"美东时间2025年4月2日，再生元制药公司成交额为5.61亿美元，成交额较昨日减少14.78%，当日成交量为90.26万股。再生元制药公司于2025年4月2日涨1.39%，报625.6美元，该股过去5个交易日跌2.27%，年初至今跌12.06%，过去60日跌12.77%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403102431a6ade930&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2468319806.SGD","LU2362540622.SGD","LU0320765992.SGD","LU2362541513.USD","LU0058720904.USD","LU0114720955.EUR","REGN","BK4585","LU1974910355.USD","LU0889565916.HKD","LU1917777945.USD","LU0109394709.USD","LU0053666078.USD","BK4588","LU0823416689.USD","LU2362541273.HKD","LU2089984988.USD","LU0289739699.SGD","LU2023250504.SGD","LU2237438978.USD","LU0882574055.USD","LU2106854487.HKD"],"gpt_icon":0},{"id":"2524813885","title":"再生元制药公司3月31日成交额为6.74亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524813885","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2524813885?lang=zh_cn&edition=full","pubTime":"2025-04-01 10:23","pubTimestamp":1743474237,"startTime":"0","endTime":"0","summary":"美东时间2025年3月31日，再生元制药公司成交额为6.74亿美元，成交额较昨日增加31.11%，当日成交量为106.63万股。再生元制药公司于2025年3月31日跌0.49%，报634.23美元，该股过去5个交易日跌4.05%，年初至今跌10.85%，过去60日跌10.85%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250401102401a4495256&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2362541513.USD","LU0289739699.SGD","LU0058720904.USD","BK4139","LU0053666078.USD","LU2023250504.SGD","LU2106854487.HKD","LU2468319806.SGD","BK4588","LU0114720955.EUR","LU2089984988.USD","LU0882574055.USD","LU0320765992.SGD","LU1974910355.USD","LU2362540622.SGD","LU2237438978.USD","LU0889565916.HKD","BK4585","LU0109394709.USD","REGN","LU0823416689.USD","LU1917777945.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2523926474","title":"小摩：维持Regeneron Pharmaceuticals评级，由增持调整至增持评级, 目标价由1100.00美元调整至1000.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2523926474","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2523926474?lang=zh_cn&edition=full","pubTime":"2025-03-31 22:49","pubTimestamp":1743432590,"startTime":"0","endTime":"0","summary":"小摩：维持Regeneron Pharmaceuticals(REGN.US)评级，由增持调整至增持评级, 目标价由1100.00美元调整至1000.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025033122541694c78a4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REGN"],"gpt_icon":0},{"id":"2523165457","title":"再生元制药公司3月28日成交额为5.14亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2523165457","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2523165457?lang=zh_cn&edition=full","pubTime":"2025-03-29 10:19","pubTimestamp":1743214749,"startTime":"0","endTime":"0","summary":"美东时间2025年3月28日，再生元制药公司成交额为5.14亿美元，成交额较昨日减少0.33%，当日成交量为80.59万股。再生元制药公司于2025年3月28日涨0.24%，报637.36美元，该股过去5个交易日跌3.21%，年初至今跌10.41%，过去60日跌9.17%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250329101911a4460bf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2106854487.HKD","LU0889565916.HKD","LU1917777945.USD","LU0320765992.SGD","LU2089984988.USD","LU2362541513.USD","LU0109394709.USD","LU0823416689.USD","LU2023250504.SGD","BK4585","LU1974910355.USD","LU2362541273.HKD","LU0053666078.USD","LU0114720955.EUR","LU0882574055.USD","BK4588","BK4139","LU2468319806.SGD","LU2362540622.SGD","REGN","LU0289739699.SGD","LU0058720904.USD","LU2237438978.USD"],"gpt_icon":0},{"id":"2522395081","title":"再生元制药公司3月26日成交额为7.99亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522395081","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2522395081?lang=zh_cn&edition=full","pubTime":"2025-03-27 10:39","pubTimestamp":1743043175,"startTime":"0","endTime":"0","summary":"美东时间2025年3月26日，再生元制药公司成交额为7.99亿美元，成交额较昨日增加46.36%，当日成交量为125.19万股。再生元制药公司于2025年3月26日涨0.95%，报640.14美元，该股过去5个交易日跌4.79%，年初至今跌10.02%，过去60日跌10.56%。该公司有多种已上市产品，包括获批用于湿性年龄相关性黄斑变性和其他眼病的低剂量Eylea 和 Eylea HD、免疫学领域的达必妥；用于降低低密度脂蛋白胆固醇的波立达；肿瘤学领域的Libtayo；以及类风湿性关节炎领域的Kevzara。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327103945a6a57ead&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2023250504.SGD","BK4588","LU0053666078.USD","LU2106854487.HKD","LU0889565916.HKD","LU1974910355.USD","LU2089984988.USD","LU0058720904.USD","LU2362540622.SGD","LU2362541273.HKD","LU2362541513.USD","BK4585","REGN","LU0320765992.SGD","LU0289739699.SGD","LU2237438978.USD","LU0823416689.USD","BK4139","LU0114720955.EUR","LU1917777945.USD","LU0882574055.USD","LU0109394709.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2520147383","title":"再生元(REGN.US)和赛诺菲(SNY.US)重磅新药新适应症拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2520147383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2520147383?lang=zh_cn&edition=full","pubTime":"2025-03-20 10:04","pubTimestamp":1742436276,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月19日，中国国家药监局药品审评中心官网最新公示，赛诺菲申报的度普利尤单抗注射液一项新适应症上市申请拟纳入优先审评，拟定适应症为大疱性类天疱疮。3月11日，再生元和赛诺菲公布了度普利尤单抗治疗中重度大疱性类天疱疮成人患者的关键性2/3期临床研究结果，该试验达到了所有主要及关键次要终点，接受度普利尤单抗治疗的患者获得持久缓解的比例是安慰剂组的5倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1264500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2362540622.SGD","LU0289739699.SGD","LU2468319806.SGD","LU0114720955.EUR","LU2362541273.HKD","LU0109394709.USD","SNY","LU0053666078.USD","LU0823416689.USD","LU1974910355.USD","IE00BFXG1179.USD","LU2089984988.USD","BK4139","LU0058720904.USD","LU0889565916.HKD","BK4588","LU2106854487.HKD","LU2362541513.USD","LU0882574055.USD","LU1917777945.USD","BK4585","BK4007","REGN","LU2237438978.USD","LU0320765992.SGD","LU2023250504.SGD"],"gpt_icon":0},{"id":"2518181927","title":"再生元(REGN)与赛诺菲(SNY)抗炎药年中或迎新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2518181927","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518181927?lang=zh_cn&edition=full","pubTime":"2025-03-11 17:21","pubTimestamp":1741684881,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再生元(REGN)与赛诺菲(SNY)在2025年美国皮肤科学会年会上公布，其IL-4/IL-13抑制剂Dupixent(达必妥)治疗中重度大疱性类天疱疮(BP)的2/3期ADEPT试验达到全部主要及关键次要终点：治疗组持续缓解率是安慰剂组的5倍。FDA已受理该适应症补充申请并授予优先审评，预计2025年年中获批。Dupixent作为全球首个获批的IL-4/IL-13双通路抑制剂，已在7大适应症(特应性皮炎、哮喘等)覆盖60多个国家，惠及超百万患者。此次新适应症针对自身免疫性大疱病，其独特的\"靶向抑制+免疫调节\"机制为传统疗法耐药患者提供新选择。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"286264","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2089984988.USD","LU2362541273.HKD","LU2023250504.SGD","LU0882574055.USD","BK4585","LU2362540622.SGD","REGN","LU2237438978.USD","LU1974910355.USD","LU2468319806.SGD","LU0053666078.USD","LU0058720904.USD","IE00BFXG1179.USD","BK4139","LU0823416689.USD","LU0889565916.HKD","LU0320765992.SGD","LU1917777945.USD","LU0114720955.EUR","LU2106854487.HKD","SNY","BK4007","LU0289739699.SGD","BK4588","LU2362541513.USD"],"gpt_icon":0},{"id":"2518464787","title":"再生元(REGN.US)和赛诺菲(SNY.US)重磅抗炎药年中有望再添新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2518464787","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518464787?lang=zh_cn&edition=full","pubTime":"2025-03-11 07:38","pubTimestamp":1741649927,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，日前，再生元和赛诺菲在2025年美国皮肤科学会年会上，公布了关键性2/3期临床试验ADEPT的积极结果。该试验评估重磅疗法Dupixent在治疗中重度大疱性类天疱疮成人患者时的疗效和安全性。ADEPT试验达到了所有主要及关键次要终点，接受Dupixent治疗的患者获得持久缓解的比例是安慰剂组的5倍。Dupixent治疗BP的补充生物制品许可申请已经获得FDA授予的优先审评资格，有望在今年年中获批。全球有超过100万名患者正在接受Dupixent治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU2468319806.SGD","IE00BFXG1179.USD","LU1917777945.USD","LU0889565916.HKD","SNY","LU0114720955.EUR","LU2362541513.USD","BK4139","BK4007","LU0053666078.USD","LU0289739699.SGD","LU2023250504.SGD","LU2089984988.USD","LU2362540622.SGD","LU0823416689.USD","LU0882574055.USD","LU0109394709.USD","REGN","LU0058720904.USD","BK4588","LU2237438978.USD","LU2106854487.HKD","LU1974910355.USD","LU2362541273.HKD","LU0320765992.SGD"],"gpt_icon":1},{"id":"2518627650","title":"再生元制药公司盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518627650","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518627650?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:00","pubTimestamp":1741618823,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日23时00分，再生元制药公司股票出现异动，股价急速拉升5.02%。截至发稿，该股报743.00美元/股，成交量32.9282万股，换手率0.30%，振幅4.63%。机构评级方面，在所有27家参与评级的机构中，67%的券商给予买入建议，30%的券商给予持有建议，3%的券商给予卖出建议。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.50%。再生元制药公司公司简介：Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310230023abf31d64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0882574055.USD","LU0320765992.SGD","LU0053666078.USD","BK4588","LU2468319806.SGD","LU2362541273.HKD","LU2106854487.HKD","LU2362541513.USD","BK4585","LU0823416689.USD","LU2362540622.SGD","LU1917777945.USD","LU2089984988.USD","LU2237438978.USD","LU2023250504.SGD","LU0109394709.USD","LU0889565916.HKD","LU0058720904.USD","BK4139","LU1974910355.USD","REGN","LU0114720955.EUR","LU0289739699.SGD"],"gpt_icon":0},{"id":"2517219051","title":"再生元制药公司涨1.93% 股价突破700美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2517219051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517219051?lang=zh_cn&edition=full","pubTime":"2025-03-07 04:32","pubTimestamp":1741293154,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日04时32分，再生元制药公司股票出现波动，股价快速拉升1.93%。截至发稿，该股报700.40美元/股，成交量46.1809万股，换手率0.42%，振幅2.46%。最近的财报数据显示，该股实现营业收入142.02亿美元，净利润44.13亿美元，每股收益40.90美元，毛利117.51亿美元，市盈率18.26倍。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.93%。再生元制药公司公司简介：Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307043234abebcea6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU0889565916.HKD","LU2089984988.USD","LU0320765992.SGD","LU2106854487.HKD","LU1917777945.USD","LU2362541513.USD","LU0058720904.USD","LU0053666078.USD","BK4585","LU0823416689.USD","BK4588","LU2362540622.SGD","LU2468319806.SGD","LU0882574055.USD","LU2362541273.HKD","LU2023250504.SGD","LU0289739699.SGD","LU0114720955.EUR","LU1974910355.USD","REGN","LU2237438978.USD","BK4139"],"gpt_icon":0},{"id":"2516634762","title":"再生元制药公司涨0.23% 股价突破700美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634762","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516634762?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012321,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，再生元制药公司股票出现波动，股价快速拉升0.23%。截至发稿，该股报700.36美元/股，成交量5414股，换手率0.00%，振幅0.55%。最近的财报数据显示，该股实现营业收入142.02亿美元，净利润44.13亿美元，每股收益40.90美元，毛利117.51亿美元，市盈率18.24倍。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.21%。再生元制药公司公司简介：Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223202989a0f7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1917777945.USD","LU0289739699.SGD","LU2023250504.SGD","BK4139","LU0109394709.USD","LU0053666078.USD","LU0058720904.USD","LU2362541273.HKD","BK4585","LU2362541513.USD","BK4588","LU2237438978.USD","LU0889565916.HKD","LU0114720955.EUR","LU2106854487.HKD","REGN","LU2362540622.SGD","LU1974910355.USD","LU0320765992.SGD","LU0823416689.USD","LU2468319806.SGD","LU0882574055.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"1166835000","title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1166835000","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166835000?lang=zh_cn&edition=full","pubTime":"2025-02-20 17:58","pubTimestamp":1740045485,"startTime":"0","endTime":"0","summary":"罗氏计划今年启动中期试验，将其与自研GLP-1减肥候选药CT-388联用。BiohavenBiohaven在一项早期肥胖试验中评估其靶向肌肉生长抑制素的药物taldefgrobep alfa。该药虽未改善脊髓性肌萎缩症患者的运动功能，但减少了总体脂肪量，并在去脂体重和骨密度方面优于安慰剂。公司将在男性肥胖患者的早期研究中评估安全性，数据预计2025年一季度公布。","market":"us","thumbnail":"https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","SRRK","ARWR","KROS","VERU","RHHBY","AZN","LLY","ELAB"],"gpt_icon":1},{"id":"2512152093","title":"赛诺菲(SNY.US)和再生元(REGN.US)的度普利尤单抗获FDA优先审查 或成为美国首款治疗BP的靶向药","url":"https://stock-news.laohu8.com/highlight/detail?id=2512152093","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512152093?lang=zh_cn&edition=full","pubTime":"2025-02-18 21:15","pubTimestamp":1739884509,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月18日，赛诺菲和再生元共同宣布FDA已受理度普利尤单抗用于治疗成人大疱性类天疱疮  的补充生物制品许可申请  的优先审查，PDUFA日期为2025年6月20日。如果获得批准，度普利尤单抗将成为美国第一个也是唯一一个治疗BP的靶向药物。BP是一种慢性、衰弱和复发性皮肤病，具有潜在的2型炎症，通常发生在老年人群中。2024年9月，度普利尤单抗治疗BP的II/III期ADEPT研究传来捷报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237438978.USD","LU2362541513.USD","BK4201","LU0882574055.USD","LU1917777945.USD","LU0320765992.SGD","BK4139","LU0162691827.USD","BK4007","LU1829250122.USD","LU2362541273.HKD","LU0072461881.USD","LU0823416689.USD","LU0289739699.SGD","LU0320765646.SGD","LU0114720955.EUR","LU0053666078.USD","LU2362540622.SGD","LU2023250504.SGD","LU2468319806.SGD","IE00BFXG1179.USD","LU2089984988.USD","LU0109394709.USD","BK4585","LU0058720904.USD","LU0889565916.HKD","SNY","REGN","LU1974910355.USD","BP","LU1162221912.USD","LU2106854487.HKD","BK4588"],"gpt_icon":0},{"id":"2510860849","title":"再生元制药公司跌1.45% 股价跌破700美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2510860849","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510860849?lang=zh_cn&edition=full","pubTime":"2025-02-11 00:52","pubTimestamp":1739206334,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日00时52分，再生元制药公司股票出现波动，股价快速跳水1.45%。截至发稿，该股报699.68美元/股，成交量23.2342万股，换手率0.21%，振幅2.60%。最近的财报数据显示，该股实现营业收入142.02亿美元，净利润44.13亿美元，每股收益40.90美元，毛利117.51亿美元，市盈率18.27倍。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.15%。再生元制药公司公司简介：Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021100521498809373&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU0889565916.HKD","LU2089984988.USD","LU0320765992.SGD","LU2106854487.HKD","LU1917777945.USD","LU2362541513.USD","LU0058720904.USD","LU0053666078.USD","BK4585","LU0823416689.USD","BK4588","LU2362540622.SGD","LU2468319806.SGD","LU0882574055.USD","LU2362541273.HKD","LU2023250504.SGD","LU0289739699.SGD","LU0114720955.EUR","LU1974910355.USD","REGN","LU2237438978.USD","BK4139"],"gpt_icon":0},{"id":"2509278030","title":"Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.","url":"https://stock-news.laohu8.com/highlight/detail?id=2509278030","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509278030?lang=zh_cn&edition=full","pubTime":"2025-02-06 21:00","pubTimestamp":1738846850,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares quadruple last year.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2025/02/TECH1_watanabe_020725-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2025/02/TECH1_watanabe_020725-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"Arcutis在2024年飙升，在皮肤科领域开辟了道路。为什么其首席执行官着眼于更大的收益。","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/arcutis-biotherapeutics-arcutis-stock-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU2491049909.HKD","IE0004445239.USD","LU1623119135.USD","REGN","LU2461242641.AUD","BK4533","IE00BJJMRZ35.SGD","ARQT","BK4599","IE00B1BXHZ80.USD","BK4588","SG9999015945.SGD","LU2362541273.HKD","LU1894683264.USD","SG9999015952.SGD","IE00BBT3K403.USD","LU0234572021.USD","LU2361044865.SGD","SG9999001176.SGD","LU1280957306.USD","BK7095","BK4550","LU1066051498.USD","LU1712237335.SGD","SG9999001176.USD","LU2089984988.USD","LU1868836914.USD","LU1267930730.SGD","LU1093756168.USD","IE00B2B36J28.USD","LU0306807586.USD","LU0058720904.USD","LU0109394709.USD","IE000M9KFDE8.USD","LLY","LU0708995401.HKD","LU0882574139.USD","SNY","LU0640476718.USD","PFE","LU1035775433.USD","LU0289739699.SGD","LU0882574055.USD","LU1061106388.HKD","BK4581","LU0354030438.USD","AZN","PFE.AU","LU2360106947.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2509422789","title":"Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509422789","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509422789?lang=zh_cn&edition=full","pubTime":"2025-02-06 20:00","pubTimestamp":1738843200,"startTime":"0","endTime":"0","summary":"- Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports dual-t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Immuneering宣布与再生元制药达成临床供应协议，评估IMM-1-104联合Libtayo®（cemiplimab）","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/06/3021891/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Regeneron-Pharmaceuticals-to-Evaluate-IMM-1-104-in-Combination-with-Libtayo-cemiplimab.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU0289739699.SGD","LU2023250504.SGD","BK4139","LU0109394709.USD","LU0053666078.USD","LU0058720904.USD","LU2362541273.HKD","BK4585","LU2362541513.USD","BK4588","LU2237438978.USD","LU0889565916.HKD","LU0114720955.EUR","LU2106854487.HKD","BK4563","REGN","LU2362540622.SGD","BK4539","LU1974910355.USD","IMRX","LU0320765992.SGD","LU0823416689.USD","LU2468319806.SGD","LU0882574055.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2509299541","title":"再生元制药公司2024财年实现净利润44.13亿美元，同比增加11.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509299541","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509299541?lang=zh_cn&edition=full","pubTime":"2025-02-06 11:01","pubTimestamp":1738810897,"startTime":"0","endTime":"0","summary":"2月6日，再生元制药公司公布财报，公告显示公司2024财年净利润为44.13亿美元，同比增加11.61%；其中营业收入为142.02亿美元，同比增加8.27%，每股基本收益为40.90美元。从资产负债表来看，再生元制药公司总负债84.06亿美元，其中短期债务--，资产负债比为4.50，流动比率为5.57。机构评级：截至2025年2月6日，当前有23家机构对再生元制药公司目标价做出预测，其中目标均价为960.26美元，其中最低目标价为575.00美元，最高目标价为1200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206110143abc4235b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REGN"],"gpt_icon":0},{"id":"2509493282","title":"再生元制药公司涨1.42% 股价突破700美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2509493282","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509493282?lang=zh_cn&edition=full","pubTime":"2025-02-05 22:32","pubTimestamp":1738765924,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日22时32分，再生元制药公司股票出现异动，股价急速拉升1.42%。截至发稿，该股报706.93美元/股，成交量2.1234万股，换手率0.02%，振幅0.75%。最近的财报数据显示，该股实现营业收入131.17亿美元，净利润39.54亿美元，每股收益37.05美元，毛利108.73亿美元，市盈率18.44倍。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.80%。再生元制药公司公司简介：Regeneron Pharmaceuticals 发现、开发和商业化用于治疗眼部疾病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205223204abc37d9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2106854487.HKD","LU0889565916.HKD","LU1917777945.USD","LU0320765992.SGD","LU2089984988.USD","LU2362541513.USD","LU0109394709.USD","LU0823416689.USD","LU2023250504.SGD","BK4585","LU1974910355.USD","LU2362541273.HKD","LU0053666078.USD","LU0114720955.EUR","LU0882574055.USD","BK4588","BK4139","LU2468319806.SGD","LU2362540622.SGD","REGN","LU0289739699.SGD","LU0058720904.USD","LU2237438978.USD"],"gpt_icon":0},{"id":"1105909979","title":"异动解读 | 再生元制药集团公布第四季度业绩超预期,推出分红及回购计划,股价大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105909979","media":"异动解读","labels":["buyback","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105909979?lang=zh_cn&edition=full","pubTime":"2025-02-05 00:10","pubTimestamp":1738685448,"startTime":"0","endTime":"0","summary":"再生元制药集团今天盘中大涨5.02%,表现强劲。该公司公布了2024年第四季度财报,业绩超出市场预期,令投资者增加看多信心。财报显示,再生元制药集团第四季度调整后每股收益为12.07美元,高于分析师平均预期的11.28美元。令投资者更加看好的是,再生元制药集团还宣布了一项每股88美分的现金分红计划,以及新增30亿美元的股票回购计划。综合以上原因,分析师对该股长期增长前景看好,推动股价今天大涨5.02%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback,movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REGN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0396},{"period":"1month","weight":-0.096},{"period":"3month","weight":-0.1497},{"period":"6month","weight":-0.3971},{"period":"1year","weight":-0.3579},{"period":"ytd","weight":-0.1428}],"compareEarnings":[{"period":"1week","weight":-0.0536},{"period":"1month","weight":-0.0696},{"period":"3month","weight":-0.0933},{"period":"6month","weight":-0.0633},{"period":"1year","weight":0.0333},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":0.03899},{"month":2,"riseRate":0.411765,"avgChangeRate":0.087815},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017742},{"month":5,"riseRate":0.647059,"avgChangeRate":0.064499},{"month":6,"riseRate":0.411765,"avgChangeRate":0.00486},{"month":7,"riseRate":0.647059,"avgChangeRate":0.053048},{"month":8,"riseRate":0.529412,"avgChangeRate":0.02165},{"month":9,"riseRate":0.470588,"avgChangeRate":0.0249},{"month":10,"riseRate":0.382353,"avgChangeRate":-0.006135},{"month":11,"riseRate":0.529412,"avgChangeRate":0.041578},{"month":12,"riseRate":0.5,"avgChangeRate":0.045405}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}